<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Electrolyte disturbances with HIV infection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Electrolyte disturbances with HIV infection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Electrolyte disturbances with HIV infection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard H Sterns, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Emmett, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 24, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyponatremia and hyperkalemia are the two major electrolyte disorders that may be associated with HIV infection. They are more likely to occur in sicker patients, with the highest rates in those who are hospitalized. In addition, hypokalemia, Fanconi syndrome, lactic acidosis, and hypophosphatemia have been described.
        </p>
        <p>
         The major electrolyte disorders that occur in patients with HIV infection will be reviewed here. A discussion of the endocrine changes seen in these patients is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/3720.html" rel="external">
          "Pituitary and adrenal gland dysfunction in patients with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          HYPONATREMIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyponatremia occurs in as many as 35 to 55 percent of hospitalized HIV-infected patients, but it can also be seen in ambulatory patients [
         <a href="#rid1">
          1-3
         </a>
         ]. The hyponatremia is usually due to one or more of three disorders, each of which is associated with an impaired ability to excrete water due to increased release of antidiuretic hormone (ADH): syndrome of inappropriate ADH secretion (SIADH), volume depletion, and adrenal insufficiency. Patients with HIV infection may be more susceptible to developing hyponatremia if water intake is high because even stable patients with normal kidney function who are not receiving medications have been shown to have an impaired response to a water load, with free water clearance that is three times lower than in healthy volunteers despite normal osmolar clearance [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Syndrome of inappropriate ADH secretion
         </span>
         <span class="headingEndMark">
          —
         </span>
         The syndrome of inappropriate ADH secretion (SIADH) is usually due to pneumonia (with
         <em>
          Pneumocystis jirovecii
         </em>
         [formerly called
         <em>
          Pneumocystis carinii
         </em>
         ] or other organisms), malignancy, or occult or symptomatic infection of the central nervous system [
         <a href="#rid1">
          1-3,5
         </a>
         ]. Among patients treated with intravenous
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         , the fluid required to dilute the drug may contribute to the development of hyponatremia. (See
         <a class="medical medical_review" href="/z/d/html/2384.html" rel="external">
          "Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Volume depletion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Volume depletion in HIV-infected patients is most often caused by gastrointestinal fluid losses, primarily from diarrhea [
         <a href="#rid1">
          1,3
         </a>
         ]. Hypovolemia can be distinguished from the SIADH by a low urine sodium concentration (usually below 15 mEq/L) and correction of the hyponatremia with volume repletion. (See
         <a class="medical medical_review" href="/z/d/html/2354.html" rel="external">
          "Diagnostic evaluation of adults with hyponatremia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Adrenal insufficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adrenal insufficiency is a much less common cause of hyponatremia than the SIADH or hypovolemia [
         <a href="#rid1">
          1,2
         </a>
         ]. In general, the fall in the plasma sodium concentration is due to cortisol deficiency (which appears to directly enhance hypothalamic ADH release), while the frequently associated hyperkalemia is due to aldosterone deficiency. (See
         <a class="medical medical_review" href="/z/d/html/2314.html" rel="external">
          "Hyponatremia and hyperkalemia in adrenal insufficiency"
         </a>
         .)
        </p>
        <p>
         The adrenal insufficiency seen in acquired immunodeficiency syndrome (AIDS) is often due to adrenalitis that may be induced by infection with cytomegalovirus, Mycobacterium avium intracellulare, or HIV itself. Adrenal hemorrhage and infiltration with Kaposi's sarcoma also may be seen. These issues are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/166.html" rel="external">
          "Causes of primary adrenal insufficiency (Addison disease)", section on 'HIV infection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2878497692">
         <span class="h2">
          Pseudohyponatremia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Marked hypertriglyceridemia or hyperproteinemia can produce "pseudohyponatremia" when the serum sodium concentration is measured with certain analytic instruments (eg, flame photometer and indirect ion-selective electrode devices). Patients with HIV may have marked polyclonal hypergammaglobulinemia, which has been reported to cause pseudohyponatremia [
         <a href="#rid6">
          6,7
         </a>
         ]. In affected patients, the serum sodium concentration will be measured as low by autoanalyzers and other analytical instruments that employ a diluting step, while it will be measured as normal by direct sodium-selective electrodes used by blood gas analyzers and some point-of-care devices. (See
         <a class="medical medical_review" href="/z/d/html/115534.html" rel="external">
          "Causes of hyponatremia without hypotonicity (including pseudohyponatremia)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H396560136">
         <span class="h1">
          HYPERNATREMIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypernatremia has been described in up to 31 percent of patients with advanced acquired immunodeficiency syndrome (AIDS). Excessive electrolyte-free water losses can occur in the setting of fever, vomiting, diarrhea, arginine vasopressin deficiency (previously called central diabetes insipidus) caused by encephalitis due to toxoplasmosis or cytomegalovirus, or arginine vasopressin resistance (previously called nephrogenic diabetes insipidus) due to interstitial nephritis or medications [
         <a href="#rid4">
          4
         </a>
         ]. Impaired renal concentrating ability has been reported in stable ambulatory patients with HIV [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          HYPERKALEMIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperkalemia has been described in up to 15 to 20 percent of hospitalized patients with HIV [
         <a href="#rid9">
          9,10
         </a>
         ]. The major causes include adrenal insufficiency, hyporeninemic hypoaldosteronism [
         <a href="#rid9">
          9
         </a>
         ], the administration of
         <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">
          trimethoprim
         </a>
         or
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         [
         <a href="#rid11">
          11-13
         </a>
         ], and impaired kidney function due to HIV-induced kidney disease or other disorders. (See
         <a class="medical medical_review" href="/z/d/html/14027.html" rel="external">
          "Overview of kidney disease in patients with HIV"
         </a>
         .)
        </p>
        <p>
         The mechanism responsible for the low renin release in HIV-infected patients is not known, nor are the relative roles of hyporeninemia and direct adrenal injury in the decreased aldosterone release. Mineralocorticoid replacement (starting with 0.05 to 0.1 mg of
         <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">
          fludrocortisone
         </a>
         per day) will usually correct the hyperkalemia induced by hypoaldosteronism [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Trimethoprim and pentamidine as potassium-sparing diuretics
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">
          Trimethoprim
         </a>
         is an important cause of hyperkalemia in patients with acquired immunodeficiency syndrome (AIDS). Trimethoprim, which is usually given in combination with sulfamethoxazole or
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         for
         <em>
          Pneumocystis jirovecii
         </em>
         pneumonia, causes an average rise in the plasma potassium concentration of 0.5 to 1 mEq/L with occasional cases of severe hyperkalemia [
         <a href="#rid11">
          11-13
         </a>
         ]. Trimethoprim is cationic, like
         <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">
          amiloride
         </a>
         and
         <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">
          triamterene
         </a>
         , and appears to act as a potassium-sparing diuretic, reversibly blocking sodium channels in the luminal membrane of the cortical collecting tubule cells [
         <a href="#rid11">
          11,13
         </a>
         ]. The ensuing reduction in sodium reabsorption then minimizes potassium secretion. (See
         <a class="medical medical_review" href="/z/d/html/2377.html" rel="external">
          "Causes and evaluation of hyperkalemia in adults", section on 'Reduced urinary potassium excretion'
         </a>
         .)
        </p>
        <p>
         The use of
         <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">
          trimethoprim
         </a>
         doses in HIV-infected patients that are often five to 10 times higher than that given for conventional infections probably explains the more frequent development of hyperkalemia among HIV-infected patients. A retrospective, single-center study of 100 HIV-infected patients treated with trimethoprim found that hyperkalemia requiring a therapeutic intervention was more common among patients treated with ≥10 mg/kg/day of trimethoprim than among those receiving lower doses [
         <a href="#rid14">
          14
         </a>
         ]. However, conventional doses of trimethoprim can also raise the plasma potassium concentration. (See
         <a class="medical medical_review" href="/z/d/html/2306.html" rel="external">
          "Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)"
         </a>
         .)
        </p>
        <p>
         An elevation in the plasma potassium concentration is also a common complication of
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         therapy [
         <a href="#rid15">
          15-17
         </a>
         ]. Pentamidine appears to act by the same mechanism as
         <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">
          trimethoprim
         </a>
         , blocking distal potassium secretion. (See
         <a class="medical medical_review" href="/z/d/html/14027.html" rel="external">
          "Overview of kidney disease in patients with HIV", section on 'Electrolyte disorders'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3745509644">
         <span class="h1">
          HYPOKALEMIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypokalemia (serum potassium &lt;3.5 mEq/L) is common in hospitalized patients with acquired immunodeficiency syndrome (AIDS), usually because of infectious diarrhea, AIDS-associated enteropathy, or vomiting [
         <a href="#rid4">
          4
         </a>
         ]. Urinary potassium wasting can occur because of tubular injury from nephrotoxic drugs. Cases of profound hypokalemia with paralysis have been reported due to potassium wasting caused by drug-induced tubulopathies associated with tenofovir [
         <a href="#rid18">
          18,19
         </a>
         ]. (See
         <a class="local">
          'Fanconi syndrome'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3344652581">
         <span class="h1">
          FANCONI SYNDROME
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">
          Tenofovir disoproxil fumarate
         </a>
         (TDF) has been associated with renal proximal tubulopathy with the Fanconi syndrome (proximal renal tubular acidosis with a normal anion gap metabolic acidosis, hypophosphatemia and osteomalacia with renal phosphate wasting, hypokalemia, hypouricemia, glycosuria with normal blood glucose, and aminoaciduria) [
         <a href="#rid18">
          18,20-22
         </a>
         ]. Risk factors for developing the syndrome include use of concomitant protease inhibitors or
         <a class="drug drug_general" data-topicid="9351" href="/z/d/drug information/9351.html" rel="external">
          didanosine
         </a>
         , genetic polymorphisms of renal transporters of tenofovir, low glomerular filtration rate (GFR), and greater circulating tenofovir levels. The tubulopathy typically resolves within two months of discontinuing the drug.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          LACTIC ACIDOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of the increased propensity to serious infection, sepsis-induced lactic acidosis can occur in patients with acquired immunodeficiency syndrome (AIDS) [
         <a href="#rid23">
          23
         </a>
         ]. In addition, there are cases in which lactic acidosis appears to result from drug-induced mitochondrial dysfunction in the absence of sepsis or hypoperfusion (type B lactic acidosis). This issue is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3765.html" rel="external">
          "Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors", section on 'Hyperlactatemia and lactic acidosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          OTHER ABNORMALITIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperuricemia and hypophosphatemia have been described with increased frequency in the era of potent antiretroviral therapy (ART). In a single-center study from France of 1232 consecutive HIV patients, hyperuricemia was present in 41 percent and hypophosphatemia in 17 percent [
         <a href="#rid24">
          24
         </a>
         ]. Protease inhibitor and non-nucleoside reverse transcriptase inhibitor therapy were significantly associated with hyperuricemia and hypophosphatemia, respectively.
        </p>
        <p class="headingAnchor" id="H566607684">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109733.html" rel="external">
          "Society guideline links: Fluid and electrolyte disorders in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22944343">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Hyponatremia (35 to 55 percent of patients), hyperkalemia (15 to 20 percent), hyperuricemia (41 percent), and hypophosphatemia (17 percent) are commonly observed among hospitalized patients with HIV infection. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hyponatremia
         </strong>
         – Hyponatremia may be caused by one of three mechanisms: the syndrome of inappropriate antidiuretic hormone secretion (SIADH), usually resulting from Pneumocystis or other pneumonia or CNS disease; adrenal insufficiency; or hypovolemia resulting from infectious diarrhea. (See
         <a class="local">
          'Hyponatremia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hyperkalemia
         </strong>
         – Hyperkalemia may be caused by adrenal insufficiency, hyporeninemic hypoaldosteronism, or the administration of
         <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">
          trimethoprim
         </a>
         or
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         ; mineralocorticoid replacement (starting with 0.05 to 0.1 mg of
         <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">
          fludrocortisone
         </a>
         per day) will usually correct the hyperkalemia induced by hypoaldosteronism. (See
         <a class="local">
          'Hyperkalemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypokalemia
         </strong>
         – Hypokalemia is common in hospitalized patients with acquired immunodeficiency syndrome (AIDS), usually because of infectious diarrhea, AIDS-associated enteropathy, or vomiting. Urinary potassium wasting can occur because of tubular injury from nephrotoxic drugs. (See
         <a class="local">
          'Hypokalemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fanconi syndrome
         </strong>
         –
         <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">
          Tenofovir disoproxil fumarate
         </a>
         (TDF) has been associated with renal proximal tubulopathy with the Fanconi syndrome. Risk factors for developing the syndrome include use of concomitant protease inhibitors or
         <a class="drug drug_general" data-topicid="9351" href="/z/d/drug information/9351.html" rel="external">
          didanosine
         </a>
         , genetic polymorphisms of renal transporters of tenofovir, low glomerular filtration rate (GFR), and greater circulating tenofovir levels. (See
         <a class="local">
          'Fanconi syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lactic acidosis
         </strong>
         – Lactic acidosis can occur in HIV-infected patients as a complication of sepsis or from drug-induced mitochondrial dysfunction in the absence of sepsis or hypoperfusion. (See
         <a class="local">
          'Lactic acidosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other abnormalities
         </strong>
         – Protease inhibitor and non-nucleoside reverse transcriptase inhibitor therapies are significantly associated with hyperuricemia and hypophosphatemia respectively. (See
         <a class="local">
          'Other abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Glassock RJ, Cohen AH, Danovitch G, Parsa KP. Human immunodeficiency virus (HIV) infection and the kidney. Ann Intern Med 1990; 112:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vitting KE, Gardenswartz MH, Zabetakis PM, et al. Frequency of hyponatremia and nonosmolar vasopressin release in the acquired immunodeficiency syndrome. JAMA 1990; 263:973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang WW, Kaptein EM, Feinstein EI, Massry SG. Hyponatremia in hospitalized patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex. Am J Med 1993; 94:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musso CG, Belloso WH, Glassock RJ. Water, electrolytes, and acid-base alterations in human immunodeficiency virus infected patients. World J Nephrol 2016; 5:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehman A, Nalintya E, Wele A, et al. Hyponatremia as a Predictor of Cryptococcal Meningitis and Death Among Asymptomatic Persons With HIV and Cryptococcal Antigenemia. Open Forum Infect Dis 2023; 10:ofad156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grateau G, Bachmeyer C, Tauléra O, et al. Pseudohyponatremia and pseudohyperphosphatemia in a patient with human immunodeficiency virus infection. Nephron 1993; 64:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garibaldi BT, Cameron SJ, Choi M. Pseudohyponatremia in a patient with HIV and hepatitis C coinfection. J Gen Intern Med 2008; 23:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belloso WH, de Paz Sierra M, Navarro M, et al. Impaired Urine Dilution Capability in HIV Stable Patients. Int J Nephrol 2014; 2014:381985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalin MF, Poretsky L, Seres DS, Zumoff B. Hyporeninemic hypoaldosteronism associated with acquired immune deficiency syndrome. Am J Med 1987; 82:1035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guy RJ, Turberg Y, Davidson RN, et al. Mineralocorticoid deficiency in HIV infection. BMJ 1989; 298:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi MJ, Fernandez PC, Patnaik A, et al. Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med 1993; 328:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg S, Reiser IW, Chou SY, Porush JG. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med 1993; 119:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velázquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 1993; 119:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caulder CR, Kocherla CS, Qureshi ZP, et al. Dose-Dependent Hyperkalemia Among Hospitalized, HIV-Infected Patients Receiving Sulfamethoxazole/Trimethoprim. Ann Pharmacother 2020; 54:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lachaal M, Venuto RC. Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine. Am J Med 1989; 87:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleyman TR, Roberts C, Ling BN. A mechanism for pentamidine-induced hyperkalemia: inhibition of distal nephron sodium transport. Ann Intern Med 1995; 122:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Preston RA, Hirsh MJ MD, Oster MD Jr, Oster HR MD. University of Miami Division of Clinical Pharmacology therapeutic rounds: drug-induced hyperkalemia. Am J Ther 1998; 5:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venkatesan EP, Pranesh MB, Gnanashanmugam G, Balasubramaniam J. Tenofovir induced Fanconi syndrome: A rare cause of hypokalemic paralysis. Indian J Nephrol 2014; 24:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cirino CM, Kan VL. Hypokalemia in HIV patients on tenofovir. AIDS 2006; 20:1671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011; 57:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol 2013; 24:1519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta SK, Anderson AM, Ebrahimi R, et al. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients. PLoS One 2014; 9:e92717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chattha G, Arieff AI, Cummings C, Tierney LM Jr. Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med 1993; 118:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isnard Bagnis C, Du Montcel ST, Fonfrede M, et al. Changing electrolyte and acido-basic profile in HIV-infected patients in the HAART era. Nephron Physiol 2006; 103:p131.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2375 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2403474" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Human immunodeficiency virus (HIV) infection and the kidney.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2299765" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Frequency of hyponatremia and nonosmolar vasopressin release in the acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8430712" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Hyponatremia in hospitalized patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26788462" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Water, electrolytes, and acid-base alterations in human immunodeficiency virus infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37008569" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Hyponatremia as a Predictor of Cryptococcal Meningitis and Death Among Asymptomatic Persons With HIV and Cryptococcal Antigenemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8366993" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Pseudohyponatremia and pseudohyperphosphatemia in a patient with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17994269" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Pseudohyponatremia in a patient with HIV and hepatitis C coinfection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24800076" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Impaired Urine Dilution Capability in HIV Stable Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3555065" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Hyporeninemic hypoaldosteronism associated with acquired immune deficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2495080" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Mineralocorticoid deficiency in HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8433730" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8328737" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Trimethoprim-sulfamethoxazole induces reversible hyperkalemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8328738" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Renal mechanism of trimethoprim-induced hyperkalemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32106685" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Dose-Dependent Hyperkalemia Among Hospitalized, HIV-Infected Patients Receiving Sulfamethoxazole/Trimethoprim.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2773964" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7992983" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A mechanism for pentamidine-induced hyperkalemia: inhibition of distal nephron sodium transport.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10099101" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : University of Miami Division of Clinical Pharmacology therapeutic rounds: drug-induced hyperkalemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24701043" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Tenofovir induced Fanconi syndrome: A rare cause of hypokalemic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16868451" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Hypokalemia in HIV patients on tenofovir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21435764" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24052632" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24651857" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8416156" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Lactic acidosis complicating the acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16557032" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Changing electrolyte and acido-basic profile in HIV-infected patients in the HAART era.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
